(Q38026862)

27 August 2017

title

Gene therapy as a vaccine for HIV-1. (English)

1 reference

27 August 2017

0 references

2

Rogier W Sanders

1 reference

27 August 2017

Ben Berkhout

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

18 July 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1315-1321

1 reference

A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

A role for carbohydrates in immune evasion in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

The role of antibodies in HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Antibody neutralization and escape by HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Immunogenicity of HIV-1 envelope glycoprotein oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Rational antibody-based HIV-1 vaccine design: current approaches and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

HIV-1 and influenza antibodies: seeing antigens in new ways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

HIV vaccine design and the neutralizing antibody problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Induction of immunity to human immunodeficiency virus type-1 by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Broad neutralization coverage of HIV by multiple highly potent antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Antibody-based protection against HIV infection by vectored immunoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Single-chain Fv-based anti-HIV proteins: potential and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Inhibition of HIV-1 by fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Towards a genetic AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Metabolic properties of IgG subclasses in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Therapeutic antibodies in HIV treatment--classical approaches to novel advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Gene therapy for severe combined immunodeficiency: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Gene therapy using adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Safety and efficacy of gene transfer for Leber's congenital amaurosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707177

10.1517/14712598.2012.707177

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference